
Best wishes for a wonderful 2025! May peace, love, good health and joy be your constant companions #happynewyear

Professor Dr Bart Van Wijmeersch Neurologist, Immunologist #MultipleSclerosis Expert @ University MS Centre, Hasselt-Pelt, Belgium

Best wishes for a wonderful 2025! May peace, love, good health and joy be your constant companions #happynewyear

What a big legacy, what a great researcher, what a great teacher, what a great visionary, what a great man… a true example and inspiration. We will miss you dearly. RIP 😔
E' mancato il Prof. Giancarlo Comi, un amico, un collega, un grande medico.

Professor Giancarlo Comi stressed the importance of listening to individuals with MS, pointing out that their experiences are a crucial tool in assessing disease progression. Read ECTRIMS’ tribute to his extraordinary legacy 👉 bit.ly/3B1xFFc #MSResearch #Neurology

Ook voor #ectrims2024 Dag 3 overloop en verduidelijk ik kort de belangrijkste topics (met een mooie afsluiter) in een korte video. youtu.be/ULSfrX42W4k?si=8GTs…


Lebrun-Frenay: Preventive healthcare in multiple sclerosis will need to focus on lifestyle and Epstein-Barr vaccination. #ECTRIMS2024

Low anti-inflammatory effect of tolebrutinib but clear effect on disease progression… but many analysis are pending: why no effect on brain atrophy/why is the effect Gd+ lesions low/… Hopefully deep dive in the data will learn us more! 🤞🏻…let’s get on this 💪🏻

Fox Rob (US): tolebrutinib vs placebo in nrSPMS (HERCULES trial) - 6m CDP: 31% decreases risk on tolebr - 3m CDP: 24% “ - 6m CDI: increased chance on tolebr - brain atrophy: no difference 🤔 Hopes are up for a change for persons with SPMS 🤞🏻👏🏻💪🏻 #ECTRIMS2024

Jiwon Oh (US): tolebrutinib vs teriflunimode in RRMS (GEMINI trials). - ARR : no difference! - 6m CDW: 29% reduction on tolebr - 3m CDW: 27% reduction on tolebr - New Gd+ lesions are higher on tolebrutinib! - T2 lesions: no difference - good safety profile #ECTRIMS2024

Chataway (UK): MS-stat2 study on simvastatin 80mg vs placebo in SPMS. Large phase 3 trial, unfortunately no significant effect on confirmed progression 🤷🏻♂️ #ECTRIMS2024

Kowalec (US) effect of genetic predisposition for depression on disease activity in #MS. Higher risk of relapse and EDSS progression in persons with higher predisposition for depression! Importance of comorbidity on MS disease course! #ECTRIMS2024

Abdelhak: effect of fingolimod and anti-CD20 treatment on sGFAP (z-scores) evolution & subsequent effect on PIRA in RRMS pts. Lowering Z-GFAP in first two years of treatment decreases PIRA risk in subsequent years by 44 (aCD20)-55%(fingo) sNFL does not add effect #ECTRIMS2024

1. Unfortunately ‘measuring’ B cell tolerance defects is cumbersome and not readily available for the clinic 🤷🏻♂️ 2. Extending the interval of course has also other goals: decreasing infections risk (and treatment costs) f.e.

Nourbakhsh (US): prospective study on anti-CD20 ‘induction’ in RRMS: 6 months treatment only. 19 pts study…but nice results. Risk of reoccurrence of disease is higher in patients with central tolerance defect @baseline! B-cell return ‘as such’ is not predictive. #ECTRIMS2024

1. Per patient, the interval seems to be quite stable (f.e. 10months every time before repopulation in same patient) 2. Cutoff used for repopulation was 10cells/ml (0,01/mcl) abs count!

Hogenboom (NL): first results of BLOOMS trial: standard vs extended interval dosing of ocrelizumab based on B-cell counts. No difference in efficacy (Relapses and MRI lesions)! (Long term results to follow) Big difference in intervals are seen (see slide) #ECTRIMS2024